{"entity":{"id":"nct04906993","kind":"trial","name":"Camrelizumab Combined With Famitinib Malate for Treatment of Recurrent/Metastatic Cervical Cancer","aka":[],"tldr":"A phase 3 trial of Camrelizumab in cervical cancer, run by Jiangsu HengRui Medicine Co., Ltd., active and no longer recruiting.","summary":"Camrelizumab Combined With Famitinib Malate for Treatment of Recurrent/Metastatic Cervical Cancer is a phase 3 interventional study registered as NCT04906993 by Jiangsu HengRui Medicine Co., Ltd., with 443 participants enrolled, started 2021-07-23 and due to reach its primary completion in 2025-06-10. Interventions recorded: camrelizumab； famitinib malate and platinum-based chemotherapy.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04906993","url":"https://clinicaltrials.gov/study/NCT04906993"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["cervical","recurrent-metastatic-cervical-cancer"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["camrelizumab"],"companies":["hengrui"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04906993","phase":"3","setting":"A Randomized, Open-Label, Controlled, Multi-Center Phase III Clinical Study of Camrelizumab Combined With Famitinib Malate Versus Platinum-based Chemotherapy in the Treatment of Recurrent/Metastatic Cervical Cancer","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","started":"2021-07-23","startedType":"actual","enrolled":443,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04906993/","neighbours":{"cancer":[{"id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/"},{"id":"recurrent-metastatic-cervical-cancer","kind":"cancer","name":"Recurrent or metastatic cervical cancer","route":"/cancers/recurrent-metastatic-cervical-cancer/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"camrelizumab","kind":"drug","name":"Camrelizumab","route":"/drugs/camrelizumab/"}],"company":[{"id":"hengrui","kind":"company","name":"Jiangsu Hengrui Pharmaceuticals","route":"/companies/hengrui/"}]}}